A study in the Blood Cancer Journal found three genetic alterations are associated with a two to three times higher risk of developing multiple myeloma for African-Americans. The findings were based on an analysis of data from samples from 881 people in the Mayo Clinic Genomics Laboratory.
Researchers demonstrated improved engraftment in adults receiving umbilical cord blood-derived stem cells using nicotinamide-based ex vivo expansion technology. They achieved a 94% rate of graft success after six weeks for adults with blood cancer, according to a Phase I/II study in the Journal of Clinical Oncology. "Although umbilical cord blood transplantation has been used for 30 years, expansion technology represents an opportunity to improve the results for adult patients," lead author Dr. Mitchell Horwitz of Duke University said.
Amgen, the Fred Hutchinson Cancer Research Center and Poseida Therapeutics presented oral abstracts at the American Society of Hematology annual meeting on bispecific antibody and anti-B-cell maturation antigen candidates.
Researchers reported in the journal Blood Advances that therapeutic phlebotomy and hydroxyurea are underutilized as treatments for elderly patients with polycythemia vera, despite being linked with reduced risk for thrombosis and improved overall survival. The retrospective study was based on data for 820 patients with a median age of 77 in the Surveillance, Epidemiology, and End Results-Medicare database.
Roche Holding has launched the FoundationOne CDx test, a companion diagnostic for personalized cancer care from Foundation Medicine, in Singapore. The test features an updated gene list compared with its predecessor and is FDA-approved in the US.
Biocartis and Genomic Health are expanding their partnership on breast health to include urology. The collaboration aims to develop an in vitro diagnostic version of Genomic Health's Oncotype DX Genomic Prostate Score test for Biocartis' Idylla platform.
UK drugmaker AstraZeneca has partnered with Belgian molecular diagnostics firm Biocartis to speed the delivery of lung cancer molecular diagnostic biomarker results in Europe. The partners will launch a prospective study in Germany, France, Belgium and Italy to determine how Biocartis' Idylla EGFR mutation test can accelerate and simplify lung cancer diagnostics through faster delivery of biomarker results.
A $2 HemoTypeSC test developed by Silver Lake Research accurately diagnosed sickle cell disease in 99.8% of 1,000 youths tested in Uganda. The dipstick-type assay can provide results within 10 minutes, is highly specific for HbA, HbS, and HbC abnormal hemoglobins and can diagnose SCD from dried blood spots.
Oxford Finance has provided Karius, a maker of infectious disease diagnostics, a senior secured facility worth $25 million. Karius plans to use the money to increase the availability of its diagnostic technology to more patients and hospitals, and to fund additional clinical trials and product innovations.
- Page 1